Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus

Introduction: Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 inhibitor prescription and ESA hyporesponsiveness (...

Full description

Bibliographic Details
Main Authors: Takeshi Hasegawa, Junhui Zhao, Brian Bieber, Jarcy Zee, Ronald L. Pisoni, Bruce M. Robinson, Norio Hanafusa, Masaomi Nangaku
Format: Article
Language:English
Published: Karger Publishers 2021-04-01
Series:Kidney & Blood Pressure Research
Subjects:
dipeptidyl peptidase-4 inhibitor
erythropoiesis-stimulating agent
hemodialysis
diabetes mellitus
Online Access:https://www.karger.com/Article/FullText/515704

Internet

https://www.karger.com/Article/FullText/515704

Similar Items